Caricamento azienda
Just reported
Q2 FY2027 results
From Haemonetics's results release of 5 novembre 2026; its quarterly report has since been filed.
Revenue
Actual
357,8M USD
+9,3% y/y
+5,4% q/qGuided
—
No guide given
EPS, GAAP
Actual
1,00 USD
+23% y/y
+39% q/qGuided
—
No guide given
Operating income, GAAP
Actual
75,1M USD
+28% y/y
+31% q/qGuided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Haemonetics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Devices
Graded A or B and worth $2B or more: A first, then the largest.
MDTMedtronic plc129,2B USDA+
SYKStryker Corp.118,9B USDA+
EWEdwards Lifesciences Corporation60,9B USDA+
GEHCGE Healthcare Technologies Inc.37B USDA
GKOSGlaukos Corp14,6B USDA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 ott 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A- EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
BIIBBiogen Inc.28 ott 2026BAGraded B, now A
Costruito dai documenti depositati da Haemonetics Corporation presso la Securities and Exchange Commission (SEC), l’autorità di vigilanza statunitense. Le cifre sono quelle dichiarate, con lo storico per azione ricalcolato sulla base azionaria di oggi. Questo descrive un’azienda: non è consulenza finanziaria né una raccomandazione di acquisto o vendita.
